{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Progression of disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Stable disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Defined as rate of complete and partial responses (at least 30% decrease in the sum of the longest diameter of target lesions), measured by CT scan or MRI of the head and neck after completion of multimodality treatment with induction TPF (Docetaxel, cisplatin and fluorouracil) chemotherapy followed by combined ERT. We will use RECIST (Response Evaluation Criteria In Solid Tumors) (Therasse et al, 2000) for evaluation of response.","groups":[{"description":"Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \\& Radiation Therapy\n\ncetuximab\n\ncisplatin\n\ndocetaxel\n\nfluorouracil\n\ncomputed tomography\n\npositron emission tomography\n\nquality-of-life assessment\n\n3-dimensional conformal radiation therapy\n\nintensity-modulated radiation therapy","id":"OG000","title":"TPFChemotherapy + Concomitant Cetuximab & RT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Best Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}